Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Completed 4Terminated 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 11Leukemia, Myeloid, Acute 5Uveal Melanoma 4Prostatic Neoplasms 4Myelodysplastic Syndromes 4Uterine Cervical Neoplasms 3Sarcoma 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Gastrointestinal Stromal Tumors 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Gliosarcoma 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Brain Neoplasms 2Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × CTLA-4 Antigen × Clear all
NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Thomas Jefferson University

Phase 2 Completed
14 enrolled 8 charts
Dermatologic

Uveal Melanoma

NCT01585194 2024-07-09

Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Completed
67 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT02519322 2024-04-05

Neoadjuvant and Adjuvant Checkpoint Blockade

M.D. Anderson Cancer Center

Phase 2 Completed
53 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT02158520 2020-01-21

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Academic and Community Cancer Research United

Phase 2 Completed
24 enrolled 10 charts
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡